• Amylyx Pharmaceuticals Co-Chief Executive Officer and director Justin B. Klee sold 100,000 common shares on November 9, 2026.
• Sales comprised 37,483 shares at $29.3917 per share; another 62,517 shares sold at $30.1062 per share.
• Klee retained direct ownership of 3,513,056 common shares, according to the Form 4 dated November 12, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-458246), on November 12, 2026, and is solely responsible for the information contained therein.